Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Therapeutic monitoring and evaluating full elimination of the drug (eg, toxicity, pregnancy).
MnemonicUnique test identifier.
LEFLUMETSP
MethodologyProcess(es) used to perform the test.
High Performance Liquid Chromatography/Mass Spectrometry
PerformedDays of the week the test is performed.
Sun, Wed, Fri
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-6 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Timing of specimen collection: Predose (trough). Obtain specimen 12 - 24 hours after last dose.
Collect
Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), or gray (sodium fluoride).
Specimen Preparation
Separate from cells within 2 hours of draw. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)
Storage/Transport Temperature
Refrigerated. Also acceptable: Room temperature or frozen.
Unacceptable Conditions
Whole blood. Potassium oxalate or separator tubes.
Remarks
Stability
Ambient: 7 days; Refrigerated: 17 days; Frozen: 90 days
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Therapeutic Range
Greater than 40.000 µg/mL
Toxic Level
Not well established.
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Therapeutic and toxic ranges are not well established. Concentrations greater than 40.000 µg/mL tend to correlate with improved patient outcome. A proposed therapeutic range is 50.000 - 100.000 µg/mL. Adverse reactions to Leflunomide, such as diarrhea, hypertension, and liver toxicity, do not correlate well with serum drug concentrations. Leflunomide has a potential risk for teratogenesis. For women being treated with Leflunomide who desire to become pregnant, enhanced drug elimination should be performed until plasma teriflunomide concentrations are lower than 0.020 µg/mL on two separate tests taken at least 14 days apart.
Compliance Category
Laboratory Developed Test (LDT)
NoteAdditional information related to the test.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Arava
Arava® (Leflunomide (Teriflunomide), Serum or Plasma)
Chat
Feedback
